Competitor Pfizer’s kid-sized vaccine doses are closer to widespread use, undergoing evaluation by the Food and Drug Administration (FDA) for nearly the same age group — starting at age 5. Moderna hasn’t yet gotten the nod to offer its vaccine to teens but is studying lower doses in younger children while it waits. Preliminary results showed vaccinated kids developed virus-fighting antibodies similar to levels that young adults produce after full-strength shots, Moderna said in a press release. The study included 4,753 kids ages 6 to 11, who got either the vaccine or dummy shots. Moderna said that like adults, the vaccinated youngsters had temporary side effects including fatigue, headache, fever and injection site pain.

Source: Indian Express October 26, 2021 01:35 UTC